| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 05/31/2000 | EP0747033B1 Transfusion liquid-containing holder and prepared transfusion liquid |
| 05/31/2000 | EP0464022B1 Insulinotropic hormone |
| 05/31/2000 | DE19854749A1 Verwendung von Kapseln, die eine oder mehrere antigene Substanzen enthalten, zur Prävention und/oder Behandlung von Autoimmunerkrankungen The use of capsules which contain one or more antigenic substances, for the prevention and / or treatment of autoimmune diseases |
| 05/31/2000 | CN1255136A Substituted 4-arylmethylene-2-imino-2,3-dihydrothiazoles and derivatives and their pharmaceutical use |
| 05/31/2000 | CN1255124A Substituted isoquinoline derivatives and their use as anticonulsants |
| 05/31/2000 | CN1255066A Plant extracts for the treatment of increase bone resorption |
| 05/31/2000 | CN1255044A Orally active fraction of momordica charactia, active peptides thereof, and their use in the treatment of diabetes |
| 05/31/2000 | CN1254594A Hypoglycemix Xiaokean capsule and its preparing process |
| 05/31/2000 | CN1052978C Process for the preparation of alpha-tocopherol |
| 05/31/2000 | CN1052893C Chinese medicinal preparation for curing infantile maldevelopment and preparation method thereof |
| 05/30/2000 | US6069162 Indolyl and benzofuranyl carboxamides as inhibitors of nitric oxide production |
| 05/30/2000 | US6069156 Indole derivatives as cGMP-PDE inhibitors |
| 05/30/2000 | US6069148 Cycloalkano-pyridines |
| 05/30/2000 | US6069147 Adjustment of metabolism |
| 05/30/2000 | US6069139 Method and composition for prophulaxis and treatment of retinal diseases |
| 05/30/2000 | CA2159326C Method for treating amyloidosis |
| 05/30/2000 | CA2153071C Derivatized calcitonins |
| 05/25/2000 | WO2000029846A2 COMPOSITIONS AND METHODS RELATING TO THE PEROXISOMAL PROLIFERATOR ACTIVATED RECEPTOR-α MEDIATED PATHWAY |
| 05/25/2000 | WO2000029623A2 Nucleic acids containing single nucleotide polymorphisms and methods of use thereof |
| 05/25/2000 | WO2000029601A1 A method for depopulating of vertebrate testis and for generation of transgenic species |
| 05/25/2000 | WO2000029583A2 Immunoglobulin superfamily proteins |
| 05/25/2000 | WO2000029446A1 Method for inhibiting macrophage infiltration using monoclonal anti-alpha-d-antibodies |
| 05/25/2000 | WO2000029435A1 12 human secreted proteins |
| 05/25/2000 | WO2000029422A1 31 human secreted proteins |
| 05/25/2000 | WO2000029384A1 2-phenylbenzimidazoles and 2-phenylindoles, and production and use thereof |
| 05/25/2000 | WO2000029383A1 Crystalline forms of 3-(2,4-dichlorobenzyl)-2-methyl-n-(pentylsulfonyl)-3h-benzimidazole-5-carboxamide |
| 05/25/2000 | WO2000029381A1 Fluorinated 3,4-dihydroquinoline derivatives used as nos inhibitors |
| 05/25/2000 | WO2000029013A1 Stable aqueous insulin preparations without phenol and cresol |
| 05/25/2000 | WO2000028991A1 Remedies for polycystic ovary syndrome |
| 05/25/2000 | WO2000028990A1 Pharmaceutical composition for modified release insulin sensitiser |
| 05/25/2000 | WO2000028989A1 Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent |
| 05/25/2000 | WO2000028983A1 Novel 4-dedimethy laminotetra cycline derivatives |
| 05/25/2000 | WO2000028981A2 Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an hmg coa reductase inhibitor |
| 05/25/2000 | WO2000028838A1 Calcium fortified juice-based nutritional supplement |
| 05/25/2000 | WO2000016797A3 Use of glp-1 or analogs in treatment of stroke |
| 05/25/2000 | WO1998049350A8 In vivo use of recombinagenic oligonucleobases to correct genetic lesions in hepatocytes |
| 05/25/2000 | DE19853487A1 Use of dialkyl fumarate for treating transplant rejection and autoimmune disease |
| 05/25/2000 | DE19853278A1 New 4-amino-2-aryl-cyclopentapyrimidine derivatives are activators of soluble guanylate cyclase, useful for treating or preventing e.g. thrombosis and restenosis |
| 05/25/2000 | CA2351576A1 Nucleic acids containing single nucleotide polymorphisms and methods of use thereof |
| 05/25/2000 | CA2351058A1 Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent |
| 05/25/2000 | CA2350785A1 31 human secreted proteins |
| 05/25/2000 | CA2350520A1 Crystal forms of 3-(2,4-dichlorobenzyl)-2-methyl-n-(pentylsulfonyl)-3h-benzimidazole-5-carboxamide |
| 05/25/2000 | CA2350501A1 Calcium fortified juice-based nutritional supplement |
| 05/25/2000 | CA2350443A1 Fluorinated 3,4-dihydroquinoline derivatives used as nos inhibitors |
| 05/25/2000 | CA2350420A1 Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an hmg coa reductase inhibitor |
| 05/25/2000 | CA2350391A1 Method for inhibiting macrophage infiltration using monoclonal anti-alpha-d-antibodies |
| 05/25/2000 | CA2349618A1 Compositions and methods relating to the peroxisomal proliferator activated receptor-.alpha. mediated pathway |
| 05/25/2000 | CA2348824A1 12 human secreted proteins |
| 05/24/2000 | EP1002802A1 Dipeptide derivatives as growth hormone secretagogues |
| 05/24/2000 | EP1002540A1 Composition comprising panax pseudo ginseng and eucommiae ulmoides |
| 05/24/2000 | EP1002075A1 Adipocyte-specific protein homologs |
| 05/24/2000 | EP1001985A1 Kringle domains 1-5 of plasminogen, capable of modulating angiogenesis in vivo |
| 05/24/2000 | EP1001976A2 Peptides having potassium channel opener activity |
| 05/24/2000 | EP1001974A1 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 05/24/2000 | EP1001973A1 Compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 05/24/2000 | EP1001971A1 Dipeptide and related compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 05/24/2000 | EP1001970A1 Dipeptide derivatives as growth hormone secretagogues |
| 05/24/2000 | EP1001944A1 Pyrazine derivatives, preparation and medicines containing them |
| 05/24/2000 | EP1001943A1 Polyhydroxyalkylpyrazine derivatives, preparation and medicines containing them |
| 05/24/2000 | EP1001942A1 Polyhydroxybutylpyrazines, their preparation and medicines containing them |
| 05/24/2000 | EP1001809A1 Decreased fat absorption with an anti-lipase antibody |
| 05/24/2000 | EP1001802A1 A combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor |
| 05/24/2000 | EP1001793A1 Chromium/biotin treatment of type ii diabetes |
| 05/24/2000 | EP1001788A1 Boron carbohydrate complexes and uses thereof |
| 05/24/2000 | EP1001784A1 Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucosidase inhibitor |
| 05/24/2000 | EP1001783A1 Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide |
| 05/24/2000 | EP1001768A1 Methods of increasing sensitivity of an individual to ob protein by upregulating ob protein receptor |
| 05/24/2000 | EP1001758A1 Use of a drug capable of modulating the regulation of upc-2 and method for screening for potential drugs against obesity |
| 05/24/2000 | EP1001755A2 Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
| 05/24/2000 | EP1001685A1 Nutritional composition containing methionine |
| 05/24/2000 | CN1254335A Nicotinamide derivatives |
| 05/24/2000 | CN1254289A Preventive or remedy for kidney diseases |
| 05/24/2000 | CN1253818A Weight-reducing lozenge and its preparation method |
| 05/24/2000 | CN1253817A Medicine preparation for curing diabetes and its preparation method |
| 05/24/2000 | CN1253809A Chinese medicine tea for diluting blood fat |
| 05/24/2000 | CN1253781A CoA oral preparation for reducing blood fat and its preparation method |
| 05/24/2000 | CN1253779A Nutrient soluble granules |
| 05/24/2000 | CN1253751A Diabetic beverage |
| 05/24/2000 | CN1253734A Bittersquash extraxt sugar-reducing milk powder and its preparation process |
| 05/24/2000 | CN1052731C Compounds with growth hormone releasing properties |
| 05/24/2000 | CN1052730C Compounds with growth hormone releasing properties |
| 05/23/2000 | US6066739 Process for producing optically active imidazole compounds, intermediates for synthesizing the same, and process for producing the same |
| 05/23/2000 | US6066678 Alkylated and crosslinked polymer comprises the reaction product of polymers of given formula having amine containing repeat units with at least one aliphatic alkylating agent and a crosslinking agent; administering to remove bile salts |
| 05/23/2000 | US6066673 Enzyme inhibitors |
| 05/23/2000 | US6066657 For the treatment of disease states associated with proteins which mediate cellular activity, for example by inhibiting tumor necrosis factor or phosphodiesterase iv |
| 05/23/2000 | US6066650 Inhibitors of microsomal triglyceride transfer protein and method |
| 05/23/2000 | US6066643 Administering to said mammal an effective amount of moxonidine, or a pharmaceutically acceptable salt thereof |
| 05/23/2000 | US6066626 Supplying active human galactosidase to cells |
| 05/23/2000 | US6066498 Compositions for the treatment and diagnosis of immune disorders |
| 05/23/2000 | US6066322 Administering antibody to treat asthma; treating helper t-cell mediated conditions |
| 05/23/2000 | CA2006818C Insulin derivatives, a process for the preparation thereof, the use thereof and a pharmaceutical formulation containing them |
| 05/18/2000 | WO2000028332A1 Methods and compositions to lower plasma cholesterol levels |
| 05/18/2000 | WO2000028323A1 Methods for identifying modulators of bs69 activity |
| 05/18/2000 | WO2000028027A2 Corticosteroid synthesis-associated genes |
| 05/18/2000 | WO2000028004A1 Virus vectors and methods of making and administering the same |
| 05/18/2000 | WO2000027879A1 Platelet-derived growth factor d, dna coding therefor, and uses thereof |
| 05/18/2000 | WO2000027850A2 Crf receptor antagonists and methods relating thereto |
| 05/18/2000 | WO2000027845A1 Spiro-indolines as y5 receptor antagonists |
| 05/18/2000 | WO2000027832A2 Thiazole derivatives as ppar gamma ligands |
| 05/18/2000 | WO2000027819A2 Antrhranilic acid amides and the use thereof as medicaments |